scholarly journals Pluripotent Stem Cells for Cardiac Cell Therapy: The Application of Cell Sheet Technology

10.5772/56326 ◽  
2013 ◽  
Author(s):  
Hidetoshi Masumoto ◽  
Jun K.
Keyword(s):  
Stem Cells ◽  
Cell Therapy ◽  
Pluripotent Stem Cells ◽  
Cell Sheet ◽  
Cardiac Cell ◽  
Cardiac Cell Therapy ◽  
Cell Sheet Technology

Placenta-derived mesenchymal stem cells for allogenic cardiac cell therapy

2012 ◽  
Vol 60 (S 01) ◽  
Author(s):  
R Roy ◽  
M Kukucka ◽  
D Messroghli ◽  
A Brodarac ◽  
M Becher ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cell Therapy ◽  
Cardiac Cell ◽  
Cardiac Cell Therapy

Abstract 3420: Potential of Human Mesenchymal Stem Cells to Differentiate into Cardiomyocytes Depends on Donor Age and Donor Tissue

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
John Van Tuyn ◽  
Daniel A Pijnappels ◽  
Marlieke L Haeck ◽  
Shoshan Knaän-Shanzer ◽  
Sicco Scherjon ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Cell Therapy ◽  
Cord Blood ◽  
Umbilical Cord Blood ◽  
Human Mesenchymal Stem Cells ◽  
Cardiac Cell ◽  
Donor Age ◽  
Cardiac Cell Therapy

Treatment of damaged myocardium using autologous adult stem cells is under intense investigation as this may regenerate lost myocardium, thereby improving cardiac function. Initial cardiac cell therapy trials using various adult stem cell types have shown beneficial effects. However in contrast to earlier animal studies no true, quantitative reconstitution of myocardium has been observed. We hypothesized that the cardiomyogenic potential of stem cells depends on donor age and cell source. We used an in vitro differentiation protocol that employs co-culture of enhanced green fluorescent protein-labeled human mesenchymal stem cells (hMSCs) with neonatal rat cardiomyocytes (nrCMCs) for 13 days, without additional chemical or mutagenic stimulation. hMSCs were either derived from adult patients, or from human fetal tissue (gestational age 18 –22 weeks) or post natally collected umbilical cord blood. Differentiation of hMSCs was assessed by the presence of a properly developed sarcomere using immunological labeling for cardiac troponin I, myosin heavy chain and actinin. Functionality of newly differentiated cardiomyocytes was assessed by the presence of a functional calcium transient in conjunction with myocyte contraction. Mesenchymal stem cells isolated from clinically relevant sources (bone marrow, fat, and synovium) of adult patients are unable to adopt a cardiomyocyte phenotype upon co-incubation with nrCMCs. In contrast, MSCs from fetal donor material all give rise to functional cardiomyocytes, although with varying efficiency (umbilical cord blood: 6.8%±3.0, bone marrow: 0.4%±1.4, liver: 1.8%±0.8, lung: 1.4%±1.3, amnion: 9.3%±5.0 [mean±SD, n=3]). Using short hairpin RNA-mediated knockdown of connexin 43 (Cx43) gene expression, we found that sarcomeric development (organization) depends on the presence of Cx43 in the differentiating stem cells. Both donor age and the tissue source of human MSCs critically influence their cardiomyogenic differentiation potential. These results suggest that these non-embryonic, fetal cells may potentially be clinically useful for cardiac cell therapy.

Regenerative Medicine/Cardiac Cell Therapy: Pluripotent Stem Cells

2017 ◽  
Vol 66 (01) ◽  
pp. 053-062 ◽  
Author(s):  
Ana Duran ◽  
Olivia Reidell ◽  
Harald Stachelscheid ◽  
Kristin Klose ◽  
Manfred Gossen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Therapy ◽  
Pluripotent Stem Cells ◽  
Cardiac Tissue ◽  
Cellular Reprogramming ◽  
Patient Specific ◽  
Cellular Cardiomyoplasty ◽  
Somatic Cell Therapy ◽  
Cardiac Cell Therapy ◽  
Induced Pluripotent

AbstractFor more than 20 years, tremendous efforts have been made to develop cell-based therapies for treatment of heart failure. However, the results of clinical trials using somatic, nonpluripotent stem or progenitor cells have been largely disappointing in both cardiology and cardiac surgery scenarios. Surgical groups were among the pioneers of experimental and clinical myocyte transplantation (“cellular cardiomyoplasty”), but little translational progress was made prior to the development of cellular reprogramming for creation of induced pluripotent stem cells (iPSC). Ever since, protocols have been developed which allow for the derivation of large numbers of autologous cardiomyocytes (CMs) from patient-specific iPSC, moving translational research closer toward clinical pilot trials. However, compared with somatic cell therapy, the technology required for safe and efficacious pluripotent stem cell (PSC)-based therapies is extremely complex and requires tremendous resources and close interactions between basic scientists and clinicians. This review summarizes PSC sources, strategies to derive CMs, current cardiac tissue engineering approaches, concerns regarding immunogenicity and cellular maturity, and highlights the contributions made by surgical groups.

Sign in / Sign up

Export Citation Format

Share Document